The Quest by Michael Lacy and Jim Larkin to make America the Land of the Free Again

America prides itself for a number of things. Chief among them liberty, democracy, bravery and most importantly, freedom. The terms “freedom” and “bravery” are patriotically sung out by every American whenever the Star-Spangled Banner is sang.

It is a country that was formed by immigrants coming from all corners of the world in search of freedom. Till this day, many immigrants escape their tumultuous backgrounds and travel to America in search of better opportunities.

It is, therefore, ironic that America has in recent years found itself in a conundrum regarding the legal status of immigrants. It has become a much-discussed topic that seriously divided opinion. There are those who are of the opinion that the country must remain true to its identity of freedom and the 14th Amendment by giving immigrants a fair hearing in front of the courts and the public’s eyes.

One such organization is the National Immigration Law Center (NILC). This organization has for the last four decades been protecting and advancing the rights of needy immigrants through impact litigation. The organization also relies on its wide legal expertise to provide policy interpretation, strategic communication, and policy advocacy, all aimed at helping immigrants.

While the organization’s contribution to protecting the rights of low-income immigrants do not go beyond the legal sphere, it also collaborates with other like-minded civil rights bodies to provide holistic help.

The National Immigration Forum is another organization working to address the plight of immigrants in America. Founded in 1982, the organization has persistently been advocating for the rights of immigrants and the value they provide for the country. The organization recognizes that there issues related to economy and security around the immigration question in America. It, therefore, seeks to provide practical input that is cognizant of these issues but remains true to America’s tolerant identity. The main areas that the forum focuses on are the integration of immigrants, humane enforcement of immigration laws and immigration policy.

Among the collection of many such organizations is a smaller one founded by Jim Larkin and Michael Lacey. The two journalist formerly co-owned two progressive media platforms: Village Voice Media and the Phoenix New Times. Learn more about Jim Larkin and Michael Lacey: and

Years of working in journalism and seeing how things can sometimes be bad on the ground left them with a yearning to help those whose civil rights were constantly being violated. They, however, lacked the resources.

These resources would ironically come by accident after Larkin and Lacey won a case against their local Sheriff Joe Arpaio. Sheriff Arpaio had previously arrested the two for, among other things, publishing his address on one of their newspapers.

However, knowing that the article constituted free speech and was thus protected by the First Amendment, Larkin and Lacey sued Maricopa County for false arrest. They won a substantial settlement of $3.75 million.

In what can only be described as a truly selfless move, Lacey and Larkin decided to use the settlement to fund their Frontera Fund. The fund would use the resources towards protecting the rights of the less advantaged in society, more specifically concentrating on migrant, civil and human rights advocacy.

Amicus Therapeutics, a Global Biotechnology Company

Amicus Therapeutics, incorporated in 2002, is a biopharmaceutical company located in New Jersey, in the United States. The company engages in the commercialization, development, and discovery of therapies that are advanced and used in orphan diseases and rare patients.

The company’s best product is Migalastat HCL, which is a molecule that is small used as a single drug or with ERT (enzymes for replacement therapy) as a combination therapy for genetic lysosomal storage disease that is rare and known as Fabry’s disease. Amicus Therapeutics investigates programs of discovery and preclinical in other rare diseases, including the deficiency of (STK9serine/threonine kinase 9).

The Michael Fox Foundation gave the company half a million US dollars as a grant, in 2010. The money was for supporting the studies carried out together with the David Geffen Medicine School at California University, Los Angeles(MarketWatch).

In the same year, ADDF (Alzheimer’s Drug Discovery Foundation) also gave Amicus a grant to support their tests study; they conducted these test with Icahn Medicine
School, based in Mount Sinai, this was done through ADRC (Alzheimer’s Disease Research Center.)

John F. Crowley served Amicus Therapeutics as the Chief Executive Officer and Chairman before leaving the company, Bradley L. Campbell works for the company as the Chief Operating Officer and President, and Chip Baird serves the company as the Chief Financial Officer since 2012.

In 2013, the company acquired Callidus Biopharma and obtained the ownership and rights for the ERT (enzyme replacement therapy), a Pompe disease treatment.

Amicus Therapeutics is in Phase III clinical trials of SD-101, a topical medication used for treating Epidermolysis bullosa, a connective tissue disease. Also, it has started clinical trials in another Lysergic acid diethylamide in Pompe disease patients. The clinical trials investigate treating the disease using a drug that has ATB200. The drug administration will involve a combination with pharmacoperone.

Checkout Amicus Therapeutics on